Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Mouse Models of Cancer Study02:43

Mouse Models of Cancer Study

Mice have long served as models for studying human biology and pathology because of their phylogenetic and physiological similarity with humans. They are also easy to maintain and breed in the laboratory, and hence, many inbred strains are now available for research. Studies on mice have contributed immeasurably to our understanding of cancer biology.
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
Mouse Models of Cancer Study02:43

Mouse Models of Cancer Study

Mice have long served as models for studying human biology and pathology because of their phylogenetic and physiological similarity with humans. They are also easy to maintain and breed in the laboratory, and hence, many inbred strains are now available for research. Studies on mice have contributed immeasurably to our understanding of cancer biology.
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Active follow-up versus passive linkage with cancer registries for case ascertainment in a cohort.

Cancer epidemiology·2016
Same author

Evidence of a healthy volunteer effect in the prostate, lung, colorectal, and ovarian cancer screening trial.

American journal of epidemiology·2007
Same author

Relationship of demographic and clinical factors to free and total prostate-specific antigen.

Urology·2001
Same author

A multi-stage model of adenoma development.

Journal of theoretical biology·2000
Same author

Prognostic factors for hematologic cancers.

Hematology/oncology clinics of North America·2000
Same author

Lung cancer among workers in chromium chemical production.

American journal of industrial medicine·2000

Related Experiment Video

Updated: Jul 24, 2026

Expedited Radiation Biodosimetry by Automated Dicentric Chromosome Identification (ADCI) and Dose Estimation
10:33

Expedited Radiation Biodosimetry by Automated Dicentric Chromosome Identification (ADCI) and Dose Estimation

Published on: September 4, 2017

Estimation and prediction for cancer screening models using deconvolution and smoothing.

P F Pinsky1

  • 1Division of Cancer Prevention, National Cancer Institute, Bethesda, Maryland 20892, USA. pp4f@nih.gov

Biometrics
|June 21, 2001
PubMed
Summary

This study introduces a new method for cancer screening analysis by assuming known underlying cancer incidence. This approach refines preclinical incidence estimation, improving accuracy for sojourn time and lead time calculations.

More Related Videos

An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

Related Experiment Videos

Last Updated: Jul 24, 2026

Expedited Radiation Biodosimetry by Automated Dicentric Chromosome Identification (ADCI) and Dose Estimation
10:33

Expedited Radiation Biodosimetry by Automated Dicentric Chromosome Identification (ADCI) and Dose Estimation

Published on: September 4, 2017

An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

Area of Science:

  • Epidemiology
  • Biostatistics
  • Mathematical Modeling

Background:

  • Cancer screening trials commonly use a convolution model relating incidence to preclinical phase duration.
  • Estimating preclinical incidence (g) and screening sensitivity requires fitting parameters, often with prior assumptions about g.

Purpose of the Study:

  • To develop a more accurate method for estimating cancer screening trial parameters by assuming known underlying incidence (I).
  • To improve estimates of sojourn time, lead time, and overdiagnosis by refining the preclinical incidence function (g).

Main Methods:

  • Utilized a convolution model where cancer incidence (I) is the convolution of preclinical incidence (g) and preclinical phase time density (f).
  • Assumed underlying incidence (I) is known, allowing preclinical incidence (g) to be solved via numerical deconvolution of f.
  • Incorporated a smoothing procedure to stabilize deconvolution and ensure a realistic g function.
  • Integrated competing mortality into the convolution model.

Main Results:

  • Eliminated the need to estimate or assume preclinical incidence (g), simplifying model fitting.
  • Achieved a realistic preclinical incidence function (g) that accurately reproduces the original incidence (I) upon convolution.
  • Demonstrated more accurate estimation of sojourn time and lead time.
  • Enabled the estimation of quantities related to overdiagnosis.

Conclusions:

  • The new method provides more accurate parameter estimations in cancer screening trials.
  • Incorporating known underlying incidence and competing mortality enhances the reliability of sojourn time and lead time estimates.
  • The refined model facilitates a better understanding of overdiagnosis in cancer screening.